Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors - Wikidata - wikimedia - TriplyDB

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

http://www.wikidata.org/entity/Q35162055

about

CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered Antibodies specifically targeting a locally misfolded region of tumor associated EGFR Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma CNTF receptor subunit α as a marker for glioma tumor-initiating cells and tumor grade: laboratory investigation.Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.Production of a novel camel single-domain antibody specific for the type III mutant EGFR.RNA interference and nonviral targeted gene therapy of experimental brain cancer Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas.Clinical applications of a peptide-based vaccine for glioblastoma.Development of an EGFRvIII specific recombinant antibody EGFRvIII-targeted vaccination therapy of malignant glioma.EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells Epidermal growth factor receptor and variant III targeted immunotherapy.Survey of the year 2000 commercial optical biosensor literature.Anti-epidermal growth factor receptor drugs in cancer therapy.Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections.All in the head: obstacles for immune rejection of brain tumours.Principles of tumor immunosurveillance and implications for immunotherapy.Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma.Immunotherapy for malignant glioma Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials.Receptor protein tyrosine phosphatase zeta as a therapeutic target for glioblastoma therapy.Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity.Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer.Monoclonal antibodies for brain tumour treatment.The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease.Small molecule and monoclonal antibody therapies in neurooncology.Immunotherapy of malignant brain tumors.Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α2.Immunotherapy for malignant glioma: current approaches and future directions.Immunotherapy for human glioma: innovative approaches and recent results.Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications.Emerging monoclonal antibody therapies for malignant gliomas.Prioritization schema for immunotherapy clinical trials in glioblastoma.Proteomic and immunologic analyses of brain tumor exosomes.Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

P2860

Q26740520-AC822C8A-E715-41C1-BAE3-3B414F86D3A9 Q27011298-C44C559C-58C5-4343-A237-735F91C885E1 Q27015045-BD7E0E2E-8DE9-4316-8AD5-F89CC8F17572 Q27654155-AB006AB5-BF0C-4CE9-ADF2-EC17FA544F5C Q28473229-DB5BF3C9-2CA4-49B1-AE71-5B504248DAAF Q30360734-6ED62917-63A1-485B-BB51-B6E4946A87BD Q30835165-97D2F475-C4F4-4B2A-AADB-E482A2423C78 Q31138512-2D30E7F2-FFE9-4621-AAE9-8B88B123D131 Q33569727-863D9DF6-5D03-4388-9D5E-D5DBFE20CB77 Q33628302-325F946E-E50B-4744-816A-B7994B06A9E0 Q33668575-FD84468E-1B8B-4124-97CE-E390D61F9767 Q33711627-91091DB4-D1F3-4C7B-AB7A-4A5AC3022734 Q33758459-821D36C7-3D80-4E72-A347-26D7FCD7E032 Q33758468-F253F7D8-5C82-448F-851D-C7B8532A752F Q34391942-04BEF943-C564-4C27-ABA7-A1741F0C1820 Q34464911-8DCB6931-3F0A-4480-BDBE-8517298AD832 Q34660837-F56BB3DA-3FBC-4AB5-830B-C243993ABC72 Q34774226-C4D65048-2ECC-4BCB-9C5E-CFF122202C0B Q34842204-5A189AEA-876B-4233-8E82-3BAAE56E3A01 Q35043113-3156C65B-088C-497F-9092-A94A187986AD Q35113661-2CE1E6EC-3A65-48CE-A1EE-CD1F1228A17A Q35114086-F3C78C61-37E8-4BF2-90F4-A7AF26DE7078 Q35659088-8FC8FA51-B7B6-4F94-9A96-989DAD7BF0FD Q35778581-33AE0F09-D68B-4BA0-8EA9-DEC1357A8365 Q35782888-AFEDF3CA-153A-4CC0-8616-7B000E239474 Q35783111-D97AE07B-B779-4891-9DC2-D29E6352E599 Q35800798-EE2A6165-E0D4-4716-9B5C-37E149781766 Q35873775-2623A557-FBA6-4A33-A937-005C3B326B0A Q35886554-772D1433-EEFC-4D8E-B724-1C3D893F6D0F Q36108119-BD37C50B-7E96-49EC-9AC3-C4F87FFF789A Q36108621-F56BD455-0D49-406F-9F0F-2A22A9BA985B Q36162929-82756D1B-464D-4C3C-B8BC-D3C6D1B5E71A Q36216327-AF33EF6B-DED5-4A49-9C6E-6A835EB06ED8 Q36273693-5E049DCE-F7F7-4A2B-A1A2-8618D45DD1E6 Q36284489-E3644196-7517-4F68-91D4-635863809568 Q36641509-18E053D6-B3FC-4273-B8B8-A03D1C8B2C78 Q36764016-5A166653-8EA0-4CE8-B27F-7791D6E153E0 Q37078999-EE25CD7A-BB65-4371-AA8A-4C4FAE6AD890 Q37159215-1E71D090-4EEB-4EC5-A46F-BE6405268BF1 Q37186248-A418D5C8-7C62-4258-A128-D0D244BA7D1E

P2860

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

http://www.wikidata.org/entity/Q35162055

description

2000 nî lūn-bûn

@nan

2000 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

@ast

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

@en

type

label

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

@ast

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

@en

prefLabel

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

@ast

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

@en

P1433

Q35162055-20461136-F32E-49E6-9DC4-53B71AED83F6

P1476

Q35162055-9B553217-1E3C-4D94-B6E6-C5349CD64DAC

P2093

Q35162055-0CA0E030-DF39-4900-BBB9-3C5AB4A554BF

Q35162055-49498962-A6B0-4C30-AA59-D45C7230B284

Q35162055-57B1DFDC-41D7-453C-9CD0-3CB981D0E6E6

Q35162055-64BB1E3E-C38C-48C1-A93E-E8ECE8412542

Q35162055-8B92CA65-CC9F-413C-9A95-A6E8E4440749

Q35162055-917CB049-D21C-42EB-83C4-E589C5FDA76E

Q35162055-9C0C2B54-2AFA-4ED2-AF4B-F5D41B2E1B47

Q35162055-B4BE1EA3-5CE9-469A-A7C8-798A4E632E94

Q35162055-DE164A9C-E0BF-47E4-9C4C-66CE86DD066F

Q35162055-FDC85CDD-0F93-416E-8FAE-F86271583BBA

P2860

Q35162055-0ACD7548-E1C2-42FA-B814-9207957BAD65

Q35162055-11625092-B1D5-4248-B715-205DD83F3871

Q35162055-1685E195-1B11-4757-8B8E-82FF7226C320

Q35162055-17738553-523F-436F-8299-2728A2A65276

Q35162055-2DE87848-3DE3-4211-8E5E-0C721D40A7F2

Q35162055-2FE38BA5-A50F-4A82-867E-2AD0DFD47721

Q35162055-30156FDD-16C0-486C-8152-9D46B34E66A1

Q35162055-374E0264-E893-4AA7-9302-CC3BA6D37E2C

Q35162055-4F6847B5-0D7E-47E0-A1B8-2EBD9B49969F

Q35162055-5055D324-3540-4789-A80F-0D2734194DE2

P304

Q35162055-BC33F8CC-32E2-4D44-9C71-7F314E5F3847

P31

Q35162055-5C7BDC58-A5C5-4585-93FB-E0CA0E9B7AF4

P356

Q35162055-3043C159-10C9-49C5-8E12-7E79B6E8B258

P407

Q35162055-C56E1540-DA57-4261-8B9A-1FEAC40B873F

P433

Q35162055-5B3F1BE6-BB7D-4613-911E-BC6F750A9AAF

P478

Q35162055-1B9DF120-40E6-4B14-9F7C-EF72321C2684

P50

Q35162055-A55E7308-C102-4F2D-8C1E-C0114BD97492

Q35162055-D2877D8C-1725-4ABC-8325-5EDE1A182014

P577

Q35162055-5CCA8932-DFBA-4A28-8276-4369BFB0E8EE

P5875

Q35162055-C71658DB-3863-4E42-9EA9-B1B891CAE51B

P698

Q35162055-813120D5-AFDD-4D78-9F58-64BE9ADE3DCF

P921

Q35162055-D77F59DB-6B13-47E2-830B-C38F8F9309E1

P932

Q35162055-8D5B0405-E39E-4980-A276-6D7E8428EBC4

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

@en

P2093

A H Friedman

http://www.w3.org/2001/XMLSchema#string

C J Wikstrand

http://www.w3.org/2001/XMLSchema#string

C Small

http://www.w3.org/2001/XMLSchema#string

D M Ashley

http://www.w3.org/2001/XMLSchema#string

G Dranoff

http://www.w3.org/2001/XMLSchema#string

G E Archer

http://www.w3.org/2001/XMLSchema#string

J H Sampson

http://www.w3.org/2001/XMLSchema#string

L E Crotty

http://www.w3.org/2001/XMLSchema#string

L P Hale

http://www.w3.org/2001/XMLSchema#string

S Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma

Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor.

Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.

Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges

Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas

Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors.

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group.

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Convection-enhanced delivery of macromolecules in the brain.

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.

P304

7503-7508

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.130166597

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P50

Darell D. Bigner

Henry Seth Friedman

P577

2000-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12465526

http://www.w3.org/2001/XMLSchema#string

P698

10852962

http://www.w3.org/2001/XMLSchema#string

P921

P932

16575

http://www.w3.org/2001/XMLSchema#string